Articles by Sabrina Ahle
Linvoseltamab drives deep, durable responses in relapsed/refractory multiple myeloma, even in high-risk patients.
Phase III MIDAS trial challenges ASCT’s role in MM, showing extended Isa-KRd may rival transplant in MRD-negative patients.
Real-world study of ide-cel in relapsed/refractory myeloma shows strong efficacy across diverse, complex patients.
Fedratinib reduced spleen size and symptoms in ruxolitinib-pretreated myelofibrosis patients in FREEDOM2 trial.
PXS-5505 shows promise in ruxolitinib-refractory myelofibrosis, improving symptoms and reducing bone marrow fibrosis.
Mosun SC shows positive ORR and CMR rates in first-line MZL, offering an effective, outpatient-friendly treatment option.
Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.
Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.
New legislation would set time limits around FDA accelerated approvals.
The designation was granted to ex vivo investigational T-cell receptor therapy NTLA-5001.
The FDA has accepted the sNDA for ivosidenib tablets as a proposed treatment for previously untreated IDH1-mutated AML.
The FDA has published draft recommendations for potential manufacturers of gene therapy products.
Mocravimod is a sphingosine 1 phosphate receptor modulator.
Researchers shared additional data on the immune response of patients with chronic myeloid leukemia to COVID-19 infection and ...
At least one-quarter of patients experienced arterial occlusive events (AOE), but rates varied depending on the approach.
Researchers surveyed the reasons for low recruitment and early closure of the UK National Cancer Research Institute’s ...
The FDA has granted accelerated approval to pacritinib for the treatment of adult patients with intermediate or high-risk.
Many side effects of the COVID-19 pandemic have disproportionately impacted older Americans.
According to a recent HHS report, the percentage of uninsured Black Americans has decreased since the ACA became law in 2010.
Oxford Biodynamics has announced the US launch of the clinical blood test.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.